HCM Risk-SCD

ورودی‌های بالینی بیمار

حداقل ۱۶ — حداکثر ۱۱۰ • واحد: years

حداقل ۱۰ — حداکثر ۴۰ • واحد: mm

حداقل ۱۵ — حداکثر ۷۰ • واحد: mm

حداقل ۰ — حداکثر ۲۰۰ • واحد: mmHg

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
scd risk
—%
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–3.999
  • Intermediate Risk4–5.999
  • High Risk6–100
Direct Clinical Answer

The HCM Risk-SCD calculates stratifying cardiovascular risk, predicting thromboembolic events, or guiding therapeutic interventions. Key inputs include age. Scores guide initiating guideline-directed medical therapy, antithrombotic or anticoagulant regimens, or urgent coronary angiography. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Estimates 5-year risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Helps determine need for implantable cardioverter defibrillator (ICD) in HCM patients.

Clinical Indication

The HCM Risk-SCD is indicated for bedside clinical practice to support Estimates 5-year risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Helps determine need for implantable cardioverter defibrillator (ICD) in HCM patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.

Limitations & Contraindications

In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.

Clinical Pearls & Action Plan

Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines.

Formula & Variables:

Prognostic Index = 0.15939858*(Max wall thickness) - 0.00294271*(Max wall thickness)² + 0.0259082*(LA diameter) + 0.00446131*(Max LVOT gradient) + 0.4583082*(Family history SCD) + 0.82639195*(NSVT) + 0.71650361*(Unexplained syncope) - 0.01799934*(Age); 5-year SCD risk (%) = 1 - 0.998^exp(Prognostic Index)

Input Parameters

NameTypeRequiredDescription
ageintegerYesAge at evaluation in years(years)
family_history_scdstringYesHistory of sudden cardiac death in ≥1 first degree relatives <40 years of age or SCD in any relative with confirmed HCM at any age
max_wall_thicknessfloatYesMaximum wall thickness - greatest thickness in anterior septum, posterior septum, lateral wall, and posterior wall of the LV measured by echocardiography(mm)
left_atrial_diameterfloatYesLeft atrial diameter determined by M-Mode or 2-D echocardiography in parasternal long axis view(mm)
max_lvot_gradientfloatYesMaximal left ventricular outflow tract gradient determined at rest and with Valsalva provocation (peak instantaneous gradient)(mmHg)
nsvtstringYesNon-sustained ventricular tachycardia - ≥3 consecutive ventricular beats at a rate of ≥120 bpm and <30 s in duration on Holter monitoring
unexplained_syncopestringYesHistory of unexplained syncope at or prior to evaluation

Score Interpretation & Guidance

RangeStageDescription
0–3.999Low RiskLow 5-year SCD risk
4–5.999Intermediate RiskIntermediate 5-year SCD risk
6–100High RiskHigh 5-year SCD risk

Evidence-Based References (EBM)

  • O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439.DOI: 10.1093/eurheartj/eht439
  • Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014 Oct 14;35(39):2733-79. doi: 10.1093/eurheartj/ehu284.DOI: 10.1093/eurheartj/ehu284
  • O'Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation. 2018 Mar 6;137(10):1015-1023.

Related calculators